Dr Mark Williams

 Professional experience

• More than 25 years of experience
• Consultant cardiologist, The Runnymede Hospital
• Consultant cardiologist, Spire St Anthony's Hospital
• Consultant cardiologist, 77 Wimpole Street Outpatients & Diagnostics
• Consultant cardiologist, Nuffield Health Guildford Hospital
• Consultant interventional cardiologist, Ashford and St Peter's Hospital NHS Foundation Trust (May 2013 - present)
• Clinical director in Cardiology, Ashford and St Peter's Hospital NHS Foundation Trust (June 2018 - November 2019)

...

 Teaching posts

• Honorary senior lecturer, St George's Hospital Medical School, University of London (Present)
• Undergraduate and postgraduate teacher, Ashford & St Peter's Hospital

 Education

• FRCP (UK) (2016)
• MD (Res), University of London (2012)
• MRCP (UK), Royal College of Physicians (2000)
• MBBS, King's College School of Medicine, University of London (1997)
• BSc, Basic Medical Sciences with Immunology, King's College London, University of London (1994)

...

 Publications and conferences

• 1994, BSc Thesis: ‘Sequence analysis and location of the idiotopes of BEG-2: A Fetal Human DNA-Binding Autoantibody. Supervisors: Prof N Staines
• MD Thesis: ‘Insights into the management of pulmonary arterial hypertension in the setting of systemic sclerosis’ Supervisors: Dr JG Coglan, Prof C Denton
• 2010, King’s College Hospital: ‘Comparison of central versus peripheral adenosine infusions in the calculation of coronary pressure measurement in patients with stable angina. Supervisor: Dr J Byrne, Dr N Melikian.
• Impact of Bosentan and endothelin-1 antagonist on the management of connective tissue disease associated pulmonary arterial hypertension. (Published and presented at the 1^st International Meeting on Pulmonary Hypertension – Cambridge 2003).
• Kawald A, Williams M, Elliott C et al. Pulmonary arterial hypertension in fibrotic and non-fibrotic SSc Patients – response to therapy. Rheumatol. 2004;43(S2):ii96.
• Williams MH, Das C, Handler CE, et al. Modern treatment algorithms improve survival in systemic sclerosis associated pulmonary hypertension. Rheumatol. 2005;44(S2):i132.
• Akram MR, Handler CE, Williams MH et al. Frequency of coronary artery disease in systemic sclerosis: Application of current probability risk assessment. Rheumatol. 2005;44(S2):i131.
• Williams MH, Handler CE, Akram MR et al. Prognostic value of brain natriuretic peptide in patients with pulmonary arterial hypertension. Heart 2005;91(S1):A58.
• Williams MH, Das C, Handler CE, et al. Improved survival of systemic sclerosis-associated pulmonary arterial hypertension in the endothelin antagonist era. Heart 2005;91(S1):A64.
• Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006 92: 926-932.
• Williams MH, Handler CE, Akram R, et al. Role on N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006: 27; 1485-1494.
• Shah NR, Meira L, Elliott RM, Howlett PJ, Brown AJ, Williams MH, West NE, Hoole S, Mahmoudi M. TCT-313 DNA repair activity determines atherosclerotic plaque stability in .patients with stable coronary artery disease. J Am Coll Cardiol 2015;66 Supl :B124 - DOI: 10.1016/j.jacc.2015.08.329.

...

 Prizes and awards

• Clinical Excellence Award (2018)
• Association of Commonwealth Universities Prize (1996)
• Sir Edward Boyle Memorial Trust Award (1996)
• Sir John Cass Foundation Award (1996)

...

 Professional membership

• General Medical Council
• Royal College of Physicians
• British Cardiovascular Society
• British Cardiovascular Interventional Society
• Medical Protection Society

...